ADAP - Adaptimmune Therapeutics (ADAP) CEO James Noble on Q4 2018 Results - Earnings Call Transcript
Adaptimmune Therapeutics plc (ADAP)
Q4 2018 Results Earnings Conference Call
February 27, 2019 08:00 PM ET
Company Participants
Juli Miller - IR
James Noble - CEO
Helen Tayton-Martin - Chief Business Officer
Adrian Rawcliffe - CFO
Rafael Amado - President, Research and Development
Conference Call Participants
Jonathan Chang - SVB Leerink
Peter Lawson - Sun Trust Robinson
Michael Schmidt - Guggenheim Securities
Marc Frahm - Cowen & Company
Reni Benjamin - Raymond James
Soumit Roy - Jones Trading
Presentation
Operator
Good day, ladies and gentlemen, and welcome to the Adaptimmune Therapeutics Conference Call. At this